Healthcare Logic for Growth

On April 23, 2026, the FDA and CMS announced the RAPID coverage pathway - a new program designed to cut the historically long gap between FDA device authorization and Medicare coverage from a year or more down to as little as two months. For early-stage life science device companies, this changes the commercial math.

In this episode, we break down exactly what RAPID is, who qualifies, what it means for your launch strategy, and five specific steps you should be taking right now.

Sources Referenced in This Episode:

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at lifesciencelogic.com or reach me at [email protected].

CONNECT

Biotech in 2026 is operating inside a Triple Threat. In this episode, we break down the three forces hitting simultaneously: capital pressure that now demands commercial readiness alongside clinical proof, clinical complexity that has turned trial design into a commercial decision, and commercial infrastructure gaps that show up at the worst possible moment - right when you need them most.

If you're leading an early-stage biotech, preparing for a Series B, or building out your first commercial team, this episode gives you an honest picture of the landscape and three clear actions you can take right now.

WHY THIS MATTERS

The playbook that worked three years ago no longer applies. Capital is concentrating at later stages and investors are asking commercial questions earlier. Payers are demanding evidence that gets built into trial design - not bolted on after approval. And the gap between FDA approval and commercial success has not gotten any shorter.

What's different in 2026 is that these three pressures are compounding each other. A weak commercial story makes fundraising harder. A misaligned trial design creates payer problems at launch. And a company that hasn't built commercial infrastructure in parallel with clinical development finds itself scrambling when the window opens. This episode is about seeing all three threats clearly - and acting on them now.

WHAT WE COVER

YOUR GO FORWARD STRATEGY — 3 ACTIONS FROM THIS EPISODE

1 - Map your trial endpoints against payer coverage criteria - do this before your next protocol amendment, not after approval

2 - Build your one-page commercial narrative before your next investor meeting - your clinical story needs a commercial chapter

3 - Book one payer conversation this quarter - not to pitch, but to listen and learn what they'll actually need to see

CONNECT

Healthcare Logic for Growth  ·  Life Science Logic  ·  [email protected]  ·  © 2026 Life Science Logic

In this opening episode of the Early-Stage Life Science series, host Eric delivers an honest 30,000-foot assessment of what early-stage life science companies are up against in 2026. Not the headline version. The operational reality.

WHY THIS EPISODE MATTERS

The life sciences landscape looks strong from the outside -  a recovering biotech index, active M&A, and AI transforming drug discovery at a real pace. But underneath those headlines, the environment for early-stage companies has quietly gotten harder.

Capital is concentrating at later stages. The regulatory and reimbursement infrastructure hasn't gotten simpler. NIH funding pullbacks are creating upstream pressure that will shape the pipeline for years. The companies that succeed in this environment are the ones who see it clearly - not the ones running on optimism alone.

This episode gives you that clear view - and a practical starting point for building commercial strategy that holds up under the pressure of 2026.

WHAT WE COVER

GO FORWARD STRATEGY - 5 ACTIONS YOU CAN TAKE THIS WEEK

01 - Run a Commercial Readiness Check - Pull up your milestone map. Next to each clinical or regulatory milestone, write the commercial question it should be answering. If you can't write one, that's your gap.

02 - Map Capital Needs Against Commercial Milestones - Every dollar should be traceable to a milestone that strengthens your next raise. Line items that don't connect? That's your first efficiency opportunity.

03 - Have the Payer Conversation Earlier Than Feels Comfortable - If you haven't spoken with a payer medical director or pharmacy director about your product and evidence strategy, schedule that meeting this week.

04 - Audit Your Visibility in the Conversations That Matter - Identify the 3–5 conferences or forums where your key stakeholders gather. Is your company present and credible there?

05 - Name Your Biggest Commercial Blind Spot - Of the five challenge areas covered today, which one is your company most exposed to right now? Name it, write it down, and bring it to your next leadership meeting as a strategic priority.

CONNECT

Healthcare Logic for Growth · Life Science Logic · [email protected]

Actionable Insights and Go-Forward-Strategies for Hospitals, Clinics, Home Health, and Emerging Healthcare Companies

Welcome to Healthcare Logic for Growth, the podcast from Life Science Logic where clinical breakthroughs meet commercial reality, where hospitals near-term challenges are discussed and translate into keeping the doors open, where healthcare leadership and their team can discover a revenue architecture that drives and sustains growth. Hosted by Eric Marr, this show is for the builders - founders, executives, clinicians, and innovators across home health, clinics, pharma, biotech, medtech, digital health, health systems, and rural hospitals. Each week, we break down the logic behind real healthcare growth. Not just the science - but the strategy. We explore go-to-market plays, market intelligence, and practical frameworks for navigating healthcare’s unique complexity. From ideation to clinical application to commercialization and adoption, we share hard-earned lessons from both failures and wins.

CONNECT

.